Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential

British Journal of Radiology

Volumn 83, Issue 991, 2010, Pages 596-603

  Skold K ^a   Gorlia, T ^b   Pellettieri, L ^a,c   Giusti, V ^a,d   H Stenstam, B ^e   Hopewell, John W ^f  

^a Hammercap Medical AB   (Sweden)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF PISA   (Italy)

^e Nykoping Hospital   (Sweden)

^f CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 BORONOPHENYLALANINE; BORON; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METHYLATION; MULTIMODALITY CANCER THERAPY; NEUTRON CAPTURE THERAPY; OVERALL SURVIVAL; PROMOTER REGION; RADIATION HAZARD; RADIATION INJURY; RETROSPECTIVE STUDY; SALVAGE THERAPY; TARGETED GENE REPAIR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DACARBAZINE; DISEASE-FREE SURVIVAL; FRUCTOSE; GLIOBLASTOMA; HUMANS; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954514990     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/56953620     Document Type: Article

References (17)

1. Barth RF, Coderre JA, Vicente MGH, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 2005;11:3987-4002.
2. Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Nat Can Inst 1993;85:704-10.
3. Mirimanoff R-O, Gorlia T, Mason W, van den Bent MJ, Kortmann RD, Fisher, B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 Phase III randomized trial. J Clin Oncol 2006;24:2563-9.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
5. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008;9:29-38.
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from Temozolomide in Glioblastoma. N Engl J Med 2005;352:997-1003.
7. Barth RF, Joensuu H. Boron neutron capture therapy for the treatment of glioblastoma and extracranial tumours: As effective, more effective or less effective than photon irradiation? Radiother Oncol 2007;82:119-22.
8. Henriksson R, Capala J, Michanek A, Lindahl, SÅ, Salford LG, Franzén L, et al. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high dose of boronophenylalanine (BPA). Radiother Oncol 2008;88:183-91.
9. Sköld K, H-Stenstam B, Diaz AZ, Giusti V, Pellettieri L, Hopewell JW. Boron neutron capture therapy for glioblastoma multiforme: advantage of prolonged infusion of BPAf. Acta Neurol Scand Doi: 10.111/i.1600-0404.2009.07. 267.
10. Coderre JA, Morris GM, Micca PL, Fisher CD, Ross GA. Comparative assessment of single-dose and fractionated boron neutron capture therapy. Radiat Res 1995;144:310-17.
11. Pellettieri L, H-Stenstam B, Rezaei A, Giusti V, Sköld K. An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand 2008;117:191-7. (Pubitemid 351190148)
12. H-Stenstam B, Pellettieri L, Sköld K, Rezaei A, Brun A. Neuropathological postmortem evaluation of BNCT for GBM. Acta Neurol Scand 2007;116:169-76.
13. Blue TE, Yanch JC. Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors. J Neurooncol 2003;62:19-31.
14. Tanaka H, Sakurai Y, Suzuki M, Masunaga S, Kinashi Y, Kashino G, et al. Characteristics comparison between a cyclotron-based neutron source and KUR-HWNIF for boron neutron capture therapy. Nucl Instr and Meth B 2009;267:1970-7.
15. Kreiner AJ, Kwan JW, Burlon AA, Di Paolo H, Henestroza E, Minsky DM, et al. A Tandem-electrostatic-quadrupole for accelerator-based BNCT. Nucl Instrum Methods B 2007;261:751-4.
16. Johannesen TB, Norum J, Lote K, Scheie D, Hirschberg H. A cost-minimizing analysis of standard radiotherapy and two experimental therapies in glioblastoma. Radiother Oncol 2002;62:227-31.
17. Nakagawa Y, Yoshihara H, Kageji T, Matsuoka R, Nakagawa Y. Cost analysis of radiotherapy, carbon ion therapy, proton therapy and BNCT in Japan. Appl Radiat Iso 2009 (suppl) 67,580-3...